GE HealthCare Launches CareIntellect for Oncology: AI Streamlines Patient Journey for Clinicians

GE HealthCare (Nasdaq: GEHC) has introduced CareIntellect for Oncology, a new cloud-based application that consolidates multi-modal patient data from various systems into a single, streamlined view. Utilizing generative AI, the application summarizes clinical notes and reports, enabling care teams to…

Read MoreGE HealthCare Launches CareIntellect for Oncology: AI Streamlines Patient Journey for Clinicians

MedTech Innovator Reveals 2024 Grand Prize and Award Winners at The MedTech Conference

MedTech Innovator (MTI), the leading accelerator for medical technology companies, has announced that Samay is the 2024 Grand Prize Winner, receiving $350,000 in non-dilutive funding. Based in Mountain View, California, and Medellín, Colombia, Samay is notable for being the first…

Read MoreMedTech Innovator Reveals 2024 Grand Prize and Award Winners at The MedTech Conference

Augurex Partners with ARUP Laboratories to Launch 14-3-3η Test for Rheumatoid Arthritis

Augurex Life Sciences Corp., a leader in autoimmune biomarker diagnostics, has announced that ARUP Laboratories, a prominent national reference lab in the U.S., has launched the 14-3-3η test as part of its diagnostic offerings. This agreement is set to significantly…

Read MoreAugurex Partners with ARUP Laboratories to Launch 14-3-3η Test for Rheumatoid Arthritis
Bayer

BeiGene Gets CHMP Nod for TEVIMBRA® in Advanced Gastric and Esophageal Cancers

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has issued positive opinions recommending an extended authorization for TEVIMBRA® (tislelizumab)…

Read MoreBeiGene Gets CHMP Nod for TEVIMBRA® in Advanced Gastric and Esophageal Cancers

Bruker Unveils $100 High-Accuracy Plasma Proteome for Glycoproteomics and Metaproteomics

At the 23rd Human Proteome Organization World Congress, Bruker Corporation (Nasdaq: BRKR) announced significant advancements in deep, unbiased, and high-sensitivity 4D-Proteomics. These developments enable robust, high-fidelity, large-scale studies while minimizing the inherent cross-talk issues associated with affinity high-plex technologies. A.…

Read MoreBruker Unveils $100 High-Accuracy Plasma Proteome for Glycoproteomics and Metaproteomics